May 2022 $22 M No. 6 $10 to $50 million 7
Vedantra Pharmaceuticals, Inc.: Raise no. 6, May 2022 × Investors in this round 7 investors had bought by the notice of Nov 2, 2022: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $22 M of $50 M offered; $28 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $989,794
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Annette Matthies · Executive Officer Christopher Haqq · Executive Officer Daniel Geffken · Executive Officer, Director Robert Connelly · Executive Officer, Director Assaf Segal · Director Carol Ashe · Director Daphne Karydas · Director Julian Adams · Director Robert Ruffolo · Director Yekaterina Chudnovsky · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Finalis Securities LLC (CRD 305908) · New York, New York Sold in all US states Signed by Robert Connelly, Chief Executive Officer. Newest notice filed Nov 2, 2022. Read the notice at the SEC .
equity SEC Jun 2020 $6 M No. 5 $2 to $10 million 49
Vedantra Pharmaceuticals, Inc.: Raise no. 5, Jun 2020 × Investors in this round 49 investors had bought by the notice of Jul 15, 2020: 49 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $30 M offered; $24 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series B Preferred Stock. The Issuer may, in its sole discretion, waive the minimum investment of $50,000. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $608,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christopher Haqq · Executive Officer · Dr. Haqq is an Executive Vice President, Head of Research and Development and the Chief Medical Officer of the Issuer. Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer. Robert Connelly · Executive Officer, Director · Mr. Connelly is the Chief Executive Officer of the Issuer. Isaac Kohlberg · Director Julian Adams · Director · Dr. Adams is the Chairman of the Board of Directors of the Issuer. Robert Ruffolo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC · New York, New York Sold in all US states Remarks in the notice On fees: “The persons named in Item 12 receive a 10% commission consisting of cash and warrants to purchase shares of the common stock of the Issuer.”Signed by Robert Connelly, Chief Executive Officer of the Issuer. Newest notice filed Jul 15, 2020. Read the notice at the SEC .
equity SEC Feb 2020 $8 M No. 4 $2 to $10 million 108
Vedantra Pharmaceuticals, Inc.: Raise no. 4, Feb 2020 × Investors in this round 108 investors had bought by the notice of Mar 13, 2020: 108 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Common Stock; Series B Preferred Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $841,180
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer. Julian Adams · Executive Officer, Director · Dr. Adams is the Executive Chairman of the Board of Directors of the Issuer. Robert Connelly · Executive Officer, Director · Mr. Connelly is the Chief Executive Officer of the Issuer. Isaac Kohlberg · Director Robert Ruffolo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC · New York, New York Sold in all US states Remarks in the notice On fees: “The persons named in Item 12 received a 10% commission consisting of cash and warrants.”Signed by Robert Connelly, Chief Executive Officer of the Issuer. Newest notice filed Mar 13, 2020. Read the notice at the SEC .
equity SEC Sep 2019 $7 M No. 3 $2 to $10 million 2
Vedantra Pharmaceuticals, Inc.: Raise no. 3, Sep 2019 × Investors in this round 2 investors had bought by the notice of Oct 15, 2019: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Series B Preferred Stock and Warrants. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer. Julian Adams · Director, Executive Officer · Mr. Adams is the Executive Chairman of the Board of Directors of the Issuer. Robert Connelly · Executive Officer, Director · Mr. Connelly is the Chief Executive Officer of the Issuer. Frank Haluska · Director Isaac Kohlberg · Director Robert Ruffolo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Merchant Capital · New York, New York Sold in all US states Remarks in the notice On fees: “The persons named in Item 12 may receive a commission from the gross proceeds of the offering.”Signed by Robert Connelly, Chief Executive Officer of the Issuer. Newest notice filed Oct 15, 2019. Read the notice at the SEC .
equity, options SEC Aug 2018 $26 M No. 2 $10 to $50 million 137
Vedantra Pharmaceuticals, Inc.: Raise no. 2, Aug 2018 × Investors in this round 137 investors had bought by the notice of Sep 14, 2018: 137 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $36 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Series B Preferred Stock and Warrants. The Issuer and the Placement Agent may mutually agree to accept lesser amounts than the minimum investment of $50,000. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $525,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Daniel Geffken · Executive Officer, Director · Mr. Geffken is the Chief Financial Officer of the Issuer. Frank Haluska · Director Isaac Blech · Director Isaac Kohlberg · Director Julian Adams · Director · Mr. Adams is the Executive Chairman of the Board of Directors of the Issuer. William Koster · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Merchant Capital · New York, New York Sold in all US states Remarks in the notice On fees: “The persons named in Item 12 will receive a commission of 10% of the gross proceeds of the offering and a percentage of the gross proceeds realized from the conversion of the promissory notes.”On the amounts: “Includes value of convertible notes and interest on such notes.”Signed by Daniel Geffken, Chief Financial Officer of the Issuer. Newest notice filed Sep 14, 2018. Read the notice at the SEC .
equity, options SEC Jul 2012 $3 M No. 1 $2 to $10 million 1
Vedantra Pharmaceuticals, Inc.: Raise no. 1, Jul 2012 × Investors in this round 1 investor had bought by the notice of Jul 31, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Alan Shaw · Executive Officer, Director, Promoter Ben Bronstein · Director Daniel Behr · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Series A Convertible Redeemable Preferred Stock”Signed by Alan Shaw, Chief Executive Officer. Newest notice filed Jul 31, 2012. Read the notice at the SEC .
equity SEC